Alexandra Ehrlich

Founder, The Strategy Blueprint Lab

For over 15 years, Alexandra Ehrlich has worked at the intersection of product strategy, biostatistics, and analytics—leading cross-functional teams through the messy middle where ideas are sparked and value is realized. She has built a career in life sciences and healthcare by turning complexity into clarity: aligning science, business, and technology so that innovation reaches the people who need it most.

With deep expertise in clinical trial methodology, real-world evidence (RWE) generation, and data commercialization, Alexandra has designed and executed pragmatic and randomized clinical trials, led statistical analysis planning, and built analytic products ranging from dashboards and workflows to full-scale data assets. She brings extensive experience in product development, go-to-market strategy, and consultative sales enablement, guiding organizations to transform bespoke services into scalable offerings, shorten time-to-value for enterprise products, and bridge the gaps between clinical stakeholders, technical teams, and executive leadership.

She has held leadership and strategic roles across healthcare, life sciences, and health technology, including positions with the Centers for Disease Control and Prevention (CDC), Kaiser Permanente, Children’s Healthcare of Atlanta, Oracle, and AstraZeneca (Evinova). Her work spans biostatistics, operational methodology, and evidence generation—ensuring methodological rigor, regulatory readiness, and market impact.

Through The Strategy Blueprint Lab, Alexandra is pioneering a new kind of consulting—one that doesn’t just optimize plans, but restores coherence between vision, people, systems, and outcomes. She champions an approach that listens deeply to data, analytic insights, and market signals, transforming them into scalable solutions, regulatory-grade evidence, and revenue-ready products that unite innovation, demand, and industry impact.

NIH Bio Sketch

Selected Publications

• Ehrlich A, et al. Improvement in Tricuspid Annular Plane Systolic Excursion with Pulmonary Hypertension Therapy in Pediatric Patients. Echocardiography. 2015; 32(8):1220-1228.

• Ehrlich A, et al. The Miniaturized Multiplane Micro-Transesophageal Echocardiographic Probe: A Comparative Evaluation of Its Accuracy and Image Quality. J Am Soc Echocardiogr. 2015; 28(7):835-842.

• Ehrlich A, et al. Association of Interstage Home Monitoring with Mortality, Readmissions, and Weight Gain: A Multicenter Study from the National Pediatric Cardiology Quality Improvement Collaborative. Circulation. 2015; 132(4):341-351.

• Ehrlich A, et al. Single Ventricle Palliation in Low Weight Patients Is Associated With Worse Early and Midterm Outcomes. Ann Thorac Surg. 2015; 99(2):668-676.

• Ehrlich A, et al. Elevated Tricuspid Regurgitant Velocity as a Marker for Pulmonary Hypertension in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2014; 36(7):e468-e472.

• Ehrlich A, et al. Novel Electrocardiographic Screening Criterion for Hypertrophic Cardiomyopathy in Children. Am J Cardiol. 2014; 113(8):1341-1346.

• Ehrlich A, et al. Cigarette Smoking Women of Reproductive Age Who Use Oral Contraceptives: Results from the 2002 and 2004 Behavioral Risk Factor Surveillance Systems. Womens Health Issues. 2010; 20(5):335-340.